Bristol Myers Squibb Presents First ADEPT Program Clinical Data
Bristol Myers Squibb announced preliminary findings from open-label periods of the ADEPT-1 and ADEPT-3 studies evaluating KarXT for psychosis associated with Alzheimer’s disease.
Bristol Myers Squibb announced preliminary findings from open-label periods of the ADEPT-1 and ADEPT-3 studies evaluating KarXT for psychosis associated with Alzheimer’s disease.